Pyxis Oncology, Inc. (PYXS)
Automate Your Wheel Strategy on PYXS
With Tiblio's Option Bot, you can configure your own wheel strategy including PYXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PYXS
- Rev/Share 0.1005
- Book/Share 1.4154
- PB 2.4162
- Debt/Equity 0.2221
- CurrentRatio 5.6543
- ROIC -0.9752
- MktCap 212102022.0
- FreeCF/Share -1.1911
- PFCF -2.8758
- PE -2.1993
- Debt/Assets 0.158
- DivYield 0
- ROE -0.828
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PYXS | Guggenheim | -- | Buy | -- | $5 | Sept. 4, 2025 |
News
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Pyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
Read More
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Pyxis Oncology, Inc. (PYXS) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PYXS's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Read More
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
Published: September 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
Read More
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders
Read More
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Read More
About Pyxis Oncology, Inc. (PYXS)
- IPO Date 2021-10-08
- Website https://www.pyxisoncology.com
- Industry Biotechnology
- CEO Lara S. Sullivan MBA
- Employees 44